Tomoyuki Monma
Fukushima Medical University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Tomoyuki Monma.
Breast Cancer | 2015
Tadashi Nomizu; Masami Matsuzaki; Naoto Katagata; Yusuke Kobayashi; Takeshi Sakuma; Tomoyuki Monma; Motonobu Saito; Fumiaki Watanabe; Shinichi Midorikawa; Yoshiko Yamaguchi
We report an extremely rare case of familial breast cancer with deleterious germline mutations in both BRCA1 and BRCA2 genes, of which, to date, no such case has been reported among Japanese breast/ovarian cancer patients. Genetic testing of the family members indicated that the same double heterozygosity for BRCA1 and BRCA2 genes was transmitted to the paternal cousin, and the same BRCA2 mutation to the younger sister with bilateral breast cancer, younger brother with stomach cancer, and proband’s son and daughter without cancer. Immunohistochemical analysis of BRCA protein expression was performed using breast cancer tissues from the proband with double heterozygosity for BRCA1 and BRCA2 genes and from her sibling without BRCA1 mutation but with BRCA2 mutation. There was no staining of either BRCA in the proband and no staining of BRCA2 in the sibling.
Oncology Letters | 2017
Takahiro Nakajima; Hirokazu Okayama; Mai Ashizawa; Masaru Noda; Keita Aoto; Motonobu Saito; Tomoyuki Monma; Shinji Ohki; Masahiko Shibata; Seiichi Takenoshita; Koji Kono
Enhancement of antibody-dependent cellular cytotoxicity (ADCC) with some modalities may be a promising approach to enhance the efficacy of therapeutic monoclonal antibodies (mAbs). It has previously been demonstrated that the removal of fucose from antibody oligosaccharides (defucosylation) leads to augmentation of ADCC activity. To establish clinically relevant evidence of this procedure, the present study evaluated trastuzumab- and cetuximab-mediated ADCC by comparing defucosylated mAbs with conventional mAbs using peripheral blood mononuclear cells (PBMCs). PBMCs were isolated from 20 patients with gastrointestinal tract cancer and 10 healthy volunteers. ADCCs were measured using PBMCs as effector cells and two gastric cancer cell lines as target cells. ADCCs were significantly enhanced with defucosylated mAbs compared with conventional mAbs using PBMC from the healthy donors and patients with cancer. The results confirmed that the cetuximab- and trastuzumab-mediated ADCCs in advanced disease were impaired in comparison to those in early disease or healthy individuals. However, when the defucosylated mAbs were used instead of the conventional mAbs, the ADCC activities in the advanced cases were almost comparable with those in early disease or healthy individuals. Furthermore, the expression of ADCC associated molecules were modified toward immunosuppressive status with a mitogen-activated protein kinase inhibitor in vitro, the conventional cetuximab- and trastuzumab-mediated ADCC was downregulated, and the defucosylated mAbs overcome the downregulation of ADCC. In conclusion, defucosylated therapeutic mAbs may enhance ADCC activities in patients with cancer, which may lead to more effective anti-cancer treatments.
Fukushima journal of medical science | 2014
Satoshi Suzuki; Yohei Watanabe; Takashi Yazawa; Teruhide Ishigame; Motoki Sassa; Tomoyuki Monma; Tadashi Takawa; Kensuke Kumamoto; Izumi Nakamura; Shinji Ohoki; Yuichi Hatakeyama; Hiroshi Sakuma; Toshiyuki Ono; Sadao Omata; Seiichi Takenoshita
BACKGROUND/AIMS We examined whether conventional ultrasonography (US) and computed tomography (CT) were useful to evaluate liver hardness and hepatic fibrosis by comparing the results with those obtained by a tactile sensor using rats with liver fibrosis. METHODOLOGY We used 44 Wistar rats in which liver fibrosis was induced by intraperitoneal administration of thioacetamide. The CT and US values of each liver were measured before laparotomy. After laparotomy, a tactile sensor was used to measure liver hardness. We prepared Azan stained sections of each excised liver specimen and calculated the degree of liver fibrosis (HFI: hepatic fibrosis index) by computed color image analysis. RESULTS The stiffness values and HFI showed a positive correlation (r=0.690, p<0.001), as did the tactile values and HFI (r=0.709, p<0.001).In addition, the stiffness and tactile values correlated positively with each other (r=0.814, p<0.001). There was no correlation between the CT values and HFI, as well as no correlation between the US values and HFI. CONCLUSION We confirmed that it was difficult to evaluate liver hardness and HFI by CT or US examination, and considered that, at present, a tactile sensor is useful method for evaluating HFI.
The Japanese Journal of Gastroenterological Surgery | 2010
Tomoyuki Monma; Yohei Watanabe; Takeshi Sakuma; Masami Matsuzaki; Naoto Katagata; Fumiaki Watanabe; Tadashi Nomizu; Seiichi Takenoshita
Journal of Clinical Oncology | 2018
Kenji Gonda; Masahiko Shibata; Daisuke Ujiie; Mai Ashizawa; Tomohiro Kikuchi; Hirokazu Okayama; Shoutarou Fujita; Wataru Sakamoto; Takahiro Nakajima; Hisahito Endo; Motonobu Saito; Tomoyuki Monma; Zenichiro Saze; Shinji Ohki; Koji Kono; Seiichi Takenoshita
Nihon Rinsho Geka Gakkai Zasshi (journal of Japan Surgical Association) | 2016
Hisashi Onozawa; Tomoyuki Monma; Izumi Nakamura; Shinji Ohki; Yoshimasa Ishii; Seiichi Takenoshita
Gan to kagaku ryoho. Cancer & chemotherapy | 2015
Shotaro Fujita; Tomoyuki Monma; Shinji Ohki; Murakami Y; Hirokazu Okayama; Yazawa T; Takawa M; Kensuke Kumamoto; Tohru Ohtake; Koji Kono; Seiichi Takenoshita
Nihon Rinsho Geka Gakkai Zasshi (journal of Japan Surgical Association) | 2014
Takashi Yazawa; Shinji Ohki; Tomoyuki Monma; Satoshi Suzuki; Izumi Nakamura; Seiichi Takenoshita
Gan to kagaku ryoho. Cancer & chemotherapy | 2014
Nakajima T; Murakami Y; Yazawa T; Shotaro Fujita; Tomoyuki Monma; Takawa M; Shinichi Suzuki; Kensuke Kumamoto; Izumi Nakamura; Ooki S; Ootake T; Seiichi Takenoshita
Nippon Daicho Komonbyo Gakkai Zasshi | 2010
Tomoyuki Monma; Tadashi Nomizu; Yohei Watanabe; Fumiaki Watanabe; Seiichi Takenoshita